英国一项新研究发现，通常用于治疗某些乳腺癌和卵巢癌的选择性雌激素受体调节剂类药物，也能有效降低女性患乳腺癌的风险。但此类药物有明显副作用，服用者应在医生指导下谨慎选择。

英国一项新研究发现,Usually used in the treatment of some selective estrogen receptor modulators of breast and ovarian cancer drugs,Also can effectively reduce the risk of women developing breast cancer.But these drugs have side effects,Users should be cautious choice under the guidance of doctors.

　　英国医学刊物《柳叶刀》日前在线刊登的一份报告说，英国伦敦大学玛丽女王学院的研究人员分析了超过8.3万名女性10年来的医疗记录，发现他莫昔芬等4种选择性雌激素受体调节剂药物可有效降低乳腺癌风险。研究显示，持续服用此类药物5年后，乳腺癌患病风险可比常规风险降低约42％，在停药后的前5年内，乳腺癌患病风险仍比常规风险低大约25％。

英国医学刊物[The lancet]recently在线刊登的一份报告说,Britain's queen Mary, university of London researchers analyzed the medical records of more than 83000 women in 10 years,Found that tamoxifen, 4 kinds of selective estrogen receptor modulator drugs can effectively reduce breast cancer risk.Studies have shown that,Continue to take these drugs after 5 years,About 42% lower risk of breast cancer risk than normal,First five years after drug withdrawal,Breast cancer risk is still about 25% lower than the normal risk.

　　研究人员说，此类药物可作用于乳腺等部位细胞中的雌激素敏感分子，对雌激素受体进行调节。虽然能降低乳腺癌风险，但这类药可能增加血栓、子宫癌等其他疾病风险，因此不适合所有女性。

研究人员说,These drugs can be applied to areas such as the mammary gland estrogen sensitive molecules in cells,Adjusted for estrogen receptor.Although can reduce the risk of breast cancer,But these drugs may increase blood clots/Risk of ovarian cancer and other diseases,Therefore is not suitable for all women.

　　领导这项研究的杰克·库济克教授说，对于有乳腺癌家族遗传史等高危女性来说，采取适当预防手段十分重要，这项研究为这些女性提供了更多选择。但由于此类药物的副作用较为明显，因此他建议特定人群应在充分咨询医生后服药。（新华）

领导这项研究的杰克·库济克教授说,For women at risk for has a history of breast cancer families, etc,Is very important to take appropriate preventive measures,The study provides more choices for these women.But because the side effects of these drugs is more obvious,So he suggested that certain people should be fully medication after consulting a doctor.(xinhua)